{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:45Z","timestamp":1786980285511,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T00:00:00Z","timestamp":1273708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s00520-010-0899-5","type":"journal-article","created":{"date-parts":[[2010,5,11]],"date-time":"2010-05-11T20:47:37Z","timestamp":1273610857000},"page":"807-813","source":"Crossref","is-referenced-by-count":90,"title":["Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin\u2013cyclophosphamide-based chemotherapy"],"prefix":"10.1007","volume":"19","author":[{"given":"David G.","family":"Warr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Street","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra D.","family":"Carides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,13]]},"reference":[{"issue":"1","key":"899_CR1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","volume":"15","author":"D Osoba","year":"1997","unstructured":"Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15(1):116\u2013123","journal-title":"J Clin Oncol"},{"key":"899_CR2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/annonc\/2.suppl_2.107","volume":"2","author":"M Tonato","year":"1991","unstructured":"Tonato M, Roila F, Del Favero A (1991) Methodology of antiemetic trials: a review. Ann Oncol 2:107\u2013114","journal-title":"Ann Oncol"},{"key":"899_CR3","unstructured":"D\u2032Acquisto R, Tyson LB, Gralla RJ (1986) The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. In: The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5:257"},{"key":"899_CR4","volume-title":"Mechanisms and control of emesis","author":"PJ Hesketh","year":"1992","unstructured":"Hesketh PJ, Plagge P, Bryson JC (1992) Single-dose ondansetron for prevention of acute cisplatin-induced emesis: analysis of efficacy and prognostic factors. In: Bianchi AL, Grelot L, Miller AD (eds) Mechanisms and control of emesis. Libbey, London"},{"issue":"5","key":"899_CR5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R","volume":"64","author":"CF Pollera","year":"1989","unstructured":"Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64(5):1117\u20131122","journal-title":"Cancer"},{"issue":"8","key":"899_CR6","first-page":"374","volume":"5","author":"CM Booth","year":"2007","unstructured":"Booth CM, Clemons M, Dranitsaris G, Joy A, Young S, Callaghan W et al (2007) Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 5(8):374\u2013380","journal-title":"J Support Oncol"},{"issue":"2 Suppl 1","key":"899_CR7","first-page":"5","volume":"5","author":"LS Schwartzberg","year":"2007","unstructured":"Schwartzberg LS (2007) Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol 5(2 Suppl 1):5\u201312","journal-title":"J Support Oncol"},{"key":"899_CR8","doi-asserted-by":"crossref","unstructured":"Jordan K, Grothey A, Pelz T, Lautenschlager C, Franke U, Schober C et al (2009) Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting. Eur J Cancer Care (Engl) (in press)","DOI":"10.1111\/j.1365-2354.2009.01099.x"},{"issue":"22","key":"899_CR9","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112\u20134119","journal-title":"J Clin Oncol"},{"issue":"12","key":"899_CR10","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090\u20133098","journal-title":"Cancer"},{"issue":"7","key":"899_CR11","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/cncr.21343","volume":"104","author":"J Herrstedt","year":"2005","unstructured":"Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104(7):1548\u20131555","journal-title":"Cancer"},{"issue":"12","key":"899_CR12","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822\u20132830","journal-title":"J Clin Oncol"},{"key":"899_CR13","doi-asserted-by":"crossref","unstructured":"Hesketh PJ, Aapro M, Street JC, Carides AD (2009) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase 3 trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer (in press)","DOI":"10.1007\/s00520-009-0737-9"},{"issue":"8","key":"899_CR14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1023\/A:1008471812316","volume":"9","author":"Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference","year":"1998","unstructured":"Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference (1998) Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol 9(8):811\u2013819","journal-title":"Ann Oncol"},{"key":"899_CR15","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology\u2014V.3.2009: antiemesis. Available at www.nccn.org\/professionals\/physician_gls\/PDF\/antiemesis.pdf . Accessed January 31, 2009."},{"issue":"18","key":"899_CR16","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","volume":"24","author":"MG Kris","year":"2006","unstructured":"Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932\u20132947","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"899_CR17","doi-asserted-by":"crossref","first-page":"i110","DOI":"10.1093\/annonc\/mdn105","volume":"19","author":"J Herrstedt","year":"2008","unstructured":"Herrstedt J, Roila F (2008) Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 19(Suppl 2):i110\u2013i112","journal-title":"Ann Oncol"},{"key":"899_CR18","first-page":"271","volume":"5","author":"Quality Oncology Practice Initiative Registration Surpasses 250 Oncology Practices: Spring 2007 Data Collection Provides Data to Drive Practitioner-Led Improvement","year":"2009","unstructured":"Quality Oncology Practice Initiative Registration Surpasses 250 Oncology Practices: Spring 2007 Data Collection Provides Data to Drive Practitioner-Led Improvement (2009) J Oncol Pract 5:271\u2013273","journal-title":"J Oncol Pract"},{"key":"899_CR19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00280-005-1005-4","volume":"56","author":"ME Jonge","year":"2005","unstructured":"Jonge ME, Huitema ADR, Holtkamp MJ, van Dam SM, Beijnen J, Rodenhuis S (2005) Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 56:370\u2013378","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15S May 20 Supp","key":"899_CR20","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/jco.2009.27.15_suppl.588","volume":"27","author":"CM Walko","year":"2009","unstructured":"Walko CM, Yu YA, Bhushan S, Spasojevic I, Carey L, Collichio F et al (2009) Effect of aprepitant (AP) on cyclophosphamide (CPA) pharmacokinetics (PK) in early breast cancer patients. J Clin Oncol 27(15S May 20 Suppl)):588","journal-title":"J Clin Oncol"},{"issue":"1","key":"899_CR21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103\u2013109","journal-title":"J Clin Oncol"},{"key":"899_CR22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1477-7525-1-46","volume":"1","author":"E Ballatori","year":"2003","unstructured":"Ballatori E, Roila F (2003) Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 1:46","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"899_CR23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s005200050078","volume":"5","author":"D Osoba","year":"1997","unstructured":"Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5(4):307\u2013313","journal-title":"Support Care Cancer"},{"issue":"2","key":"899_CR24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00520-004-0745-8","volume":"13","author":"MS Aapro","year":"2005","unstructured":"Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13(2):117\u2013121","journal-title":"Support Care Cancer"},{"issue":"3","key":"899_CR25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/cncr.22823","volume":"110","author":"YC Tina Shih","year":"2007","unstructured":"Tina Shih YC, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110(3):678\u2013685","journal-title":"Cancer"},{"issue":"1","key":"899_CR26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mdj078","volume":"17","author":"F Roila","year":"2006","unstructured":"Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17(1):20\u201328","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"899_CR27","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1093\/annonc\/mdi805","volume":"16","author":"J Herrstedt","year":"2005","unstructured":"Herrstedt J, Aapro MS, Roila F, Kataja VV (2005) ESMO minimum clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 16(Suppl 1):i77\u2013i79","journal-title":"Ann Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-010-0899-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-010-0899-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-010-0899-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T11:37:36Z","timestamp":1635334656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-010-0899-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,13]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1007\/s00520-010-0899-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,13]]}}}